Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset for weight loss.

Original title: “Lilly cracks down on black market for obesity asset retatrutide with six lawsuits”

Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.

Original title: “7 companies hiring in North Carolina now”

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

Original title: “Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines”

BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.

Original title: “BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations”

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Original title: “Boulevard starts up with $65M to pursue targeted autoimmune drugs”

A missed promotion can feel like a verdict on your potential. But people and organizations do not always develop at the same pace. Executive coach Angela Justice breaks down what a missed promotion is actually telling you—and what it isn’t.

Original title: “Why a missed promotion isn't always about you”

AI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.

Original title: “With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development”

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL- 12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

Original title: “NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.

Original title: “Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

Original title: “Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop a collection of anti- CE1 antibodies for liver cancer treatment.

Original title: “Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer”

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OptoSurgical LLC ("OptoSurgical"), a company located in Columbia, Maryland, the United States of America.

Original title: “Prospective Grant of an Exclusive Patent License: Development and Commercialization of BL-760 Dye for Intraoperative Fluorescence Imaging”

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Original title: “Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs”